ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents

Does Risk Factor Control Influence Pioglitazone’s Cardiovascular Benefits after Stroke?

A reduction in myocardial infarction (MI) or recurrent stoke with pioglitazone in insulin-resistant patients without diabetes mellitus (DM) was evident even in patients who did not achieve standard prevention strategy goals.

Conclusion: The contribution of pioglitazone on reducing risk for recurrent stroke or MI after stroke among insulin-resistant, non-DM patients appeared independent of whether standard, evidence-based prevention strategies are achieved. Link to Abstract.

Cardiovascular Safety of Canagliflozin vs Other Antidiabetic Agents in Routine Care

A comparison of canagliflozin (CANA) to other antidiabetic agents (DPP-4 inhibitor, sulfonylurea, GLP-1 agonist) in the routine care of patients with type 2 diabetes revealed a similar risk of coronary disease or stroke, but a lower risk of heart failure.

Conclusion: Canaglifozin use was associated with a similar risk of coronary disease or stroke as with non-gliflozin antidiabetic agents, but with a lower risk of heart failure. Link to Abstract.

SGLT2i is Associated with Lower Risk of Mortality and Heart Failure Compared with Other Glucose-lowering Drugs: A Three-Country Analysis

The class of sodium-glucose-cotransporter-2-inibitors (SGLT2i), including dapagliflozin, empagliflozin, and canagliflozin, was compared to other antidiabetic drugs for risk of all-cause mortality and heart failure.

Conclusion: In type 2 diabetes, treatment with an SGLT2i was associated with lower rates of all-cause mortality and of hospitalization for heart failure compared to other oral antidiabetics. Link to Abstract.